COMMUNIQUÉS West-GlobeNewswire

Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
18/12/2025
BOCA RATON, FLA, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a biotech company focused on advancing cancer treatments, today announced that it has entered into [...]
TOMI Environmental Solutions Secures a Purchase Order of Approximately $500,000 for the Integration of SteraMist iHP Technology within a Global Biopharmaceutical Leader
18/12/2025
FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, announced today announced it has received a [...]
ENvue Medical’s UroShield® Kit Secures Reimbursement in the UK
18/12/2025
Peak Medical, ENvue’s Exclusive Distributor in UK, Places Significant Order after Reimbursement Decision, Projecting Future Market Demand for UroShield® Kit TYLER, Texas, Dec. 18, 2025 (GLOBE NEWSWIRE) -- ENvue Medical [...]
Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference
18/12/2025
- The overview presentation will review some of the Company’s recent achievements as well as the outlook for upcoming data milestones - JERUSALEM, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", [...]
SafeSpace Global Enters Letter of Intent with BMRT for Exclusive Deployment of Molecular-Level Weapons Detection Technology in U.S. Schools and Correctional Facilities
18/12/2025
Letter of Intent Contemplates Joint Venture and Exclusive Deployment Rights Across Estimated $6 Billion Addressable Market Knoxville, TN, Dec. 18, 2025 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID:SSGC) (“ [...]
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device
18/12/2025
-- Innovative single-device solution integrates proven FemVue and FemChec ® technologies to support fallopian tube evaluation and improve workflow efficiency-- ATLANTA, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. ( [...]
J-Star Announces Interim Financial Results for the First Six Months of 2025
18/12/2025
TAICHUNG CITY, Taiwan, Dec. 18, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions across a wide range of [...]
Therapy for Women Joins the Lumina Therapy Alliance, Strengthening a National Network Serving Employers and Their Workforces
18/12/2025
Broadening national access to in-person care, with specialized expertise supporting women in high-performance workplaces NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lumina Therapy Alliance , the nation’s leading [...]
Crucial Innovations Retains FOCUS Capital Partners to Support Strategic Growth and Investment Initiatives
18/12/2025
LONDON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crucial Innovations Corp . (“CINV” or “the Company”), an international pioneering medical cannabis company, announced that it has formally retained FOCUS Capital Partners (“ [...]
NeuExcell Therapeutics Reports Encouraging Clinical Results with World’s First In Situ Conversion Therapy for Malignant Glioma
18/12/2025
SINGAPORE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- NeuExcell Therapeutics announced encouraging clinical results of NXL-004, the world’s first in situ conversion gene therapy for malignant glioma. The data were presented at [...]
Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company
18/12/2025
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) [...]
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
18/12/2025
Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer’s disease Clear and near-term value inflection points, with blinded 6-month interim data [...]
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
18/12/2025
Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer’s disease Clear and near-term value inflection points, with blinded 6-month interim data [...]
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
18/12/2025
NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's [...]
“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine
18/12/2025
Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to new treatments for advanced cancers and long COVID BriaCell’s Phase 3 clinical [...]
Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference
18/12/2025
WALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the J.P. Morgan [...]
Enable Injections Announces Regulatory Approval in Saudi Arabia for the EMPAVELI® Injector based on enFuse® Technology
18/12/2025
CINCINNATI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse ® On-Body Delivery System, today announced that the EMPAVELI ® [...]
Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement
18/12/2025
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES HALIFAX, Nova Scotia, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ [...]
Microbix Reports Results for Q4 and Fiscal 2025
18/12/2025
Full-Year Revenues of $18.6 million and Net Loss of $2.2 million MISSISSAUGA, Ontario, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, [...]

Pages